Ultralife Reports Q1 Net Loss and Revenue Decline Amidst Ongoing Material Weakness in Internal Controls
summarizeSummary
Ultralife Corp reported a net loss of $0.03 per share for Q1 2026, a significant decline from a profit in the prior year, alongside a 6.5% revenue decrease and an ongoing material weakness in internal controls.
check_boxKey Events
-
Shift to Net Loss
The company reported a net loss of $0.451 million, or $0.03 per share, for Q1 2026, a significant reversal from a net income of $1.865 million, or $0.11 per share, in Q1 2025.
-
Revenue Decline
Consolidated revenues decreased by 6.5% to $47.445 million in Q1 2026, down from $50.746 million in the prior-year period, reflecting declines in both commercial and government/defense sales.
-
Gross Margin Compression
Gross profit declined to $10.110 million (21.3% of revenue) in Q1 2026, from $12.745 million (25.1% of revenue) in Q1 2025, primarily due to sales product mix, higher utility costs, and one-time production delays.
-
Operating Loss Reported
Operating results swung to a loss of $0.215 million in Q1 2026, compared to an operating income of $3.399 million in Q1 2025, driven by lower revenues, reduced gross margin, and increased operating expenses, including $0.847 million in one-time, non-recurring costs.
auto_awesomeAnalysis
Ultralife Corporation's Q1 2026 results show a significant deterioration in financial performance, with a swing from net income to a net loss and a notable decline in revenue and gross margin. This negative financial trend is compounded by the disclosure of an ongoing material weakness in internal control over financial reporting, which was previously reported in the 2025 10-K and remains unremediated. The material weakness raises concerns about the reliability of financial reporting and operational efficiency. Investors should monitor the company's progress in addressing these control deficiencies and the impact of declining sales and margins on future profitability and cash flow. This detailed 10-Q follows a Reuters news alert and an 8-K filing on the same day, providing comprehensive financial context to the previously announced top-line figures.
At the time of this filing, ULBI was trading at $6.71 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $117.4M. The 52-week trading range was $4.50 to $9.52. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.